Barry Littlejohns was named President, Biologics & Specialty Drug Delivery in October 2017.  Previously, Mr Littlejohns was named President of Catalent’s Drug Delivery Systems Solutions in July 2013.  Prior to that, he led Catalent’s Medication Delivery Solutions business from July 2011 to July 2013.Mr. Littlejohns has an extensive background in leading international life science businesses in both US and European organizations. He rejoins Catalent after two years as Senior Vice President of Operations and Business Development at Danish biotechnology company Genmab, where his responsibilities included strategic licensing and manufacturing oversight. Prior to Genmab, he served in a broad range of leadership roles at Catalent. These include Vice President of Global Business Operations, Vice President of Commercial Affairs for Medication Delivery Solutions, Vice President and General Manager of Injectables, and various financial, operational and leadership roles. Barry Littlejohns was named President, Biologics & Specialty Drug Delivery in October 2017.  Previously, Mr Littlejohns was named President of Catalent’s Drug Delivery Systems Solutions in July 2013.  Prior to that, he led Catalent’s Medication Delivery Solutions business from July 2011 to July 2013.Mr. Littlejohns has an extensive background in leading international life science businesses in both US and European organizations. He rejoins Catalent after two years as Senior Vice President of Operations and Business Development at Danish biotechnology company Genmab, where his responsibilities included strategic licensing and manufacturing oversight. Prior to Genmab, he served in a broad range of leadership roles at Catalent. These include Vice President of Global Business Operations, Vice President of Commercial Affairs for Medication Delivery Solutions, Vice President and General Manager of Injectables, and various financial, operational and leadership roles.

Intrested in business management.